Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients
BACKGROUND: CD28(neg) T cells, which display functional characteristic of oligoclonally expanded cytotoxic memory T lymphocytes, are believed to be pathologically relevant in rheumatoid arthritis manifestation. The CD28 co-stimulation blockade by abatacept can prevent the generation of CD28(neg) T-cell populations in these patients.
METHODS: Samples were obtained before and after 12 months of abatacept therapy. T-cell phenotype and T-cell receptor diversity were evaluated by flow cytometry and complementarity-determining region-3 spectratyping, respectively, while telomerase reverse-transcriptase gene level was measured by real-time PCR.
RESULTS: Abatacept induces a decrease of the percentage and number of CD4(+)CD28(neg) T cells and a reduction of T-cell repertoire restrictions; these features are directly correlated. Thymic output and telomerase activity are not modified by the therapy.
CONCLUSIONS: Abatacept-induced decrease of peripheral T-cell repertoire restrictions can due to a reduced generation of senescent, chronically stimulated CD4(+)CD28(neg) T cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 13(2015) vom: 16. Jan., Seite 12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Imberti, Luisa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7D0YB67S97 |
|---|
| Anmerkungen: |
Date Completed 14.03.2016 Date Revised 13.11.2018 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12967-014-0363-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM245381910 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM245381910 | ||
| 003 | DE-627 | ||
| 005 | 20231224140746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-014-0363-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0818.xml |
| 035 | |a (DE-627)NLM245381910 | ||
| 035 | |a (NLM)25592982 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Imberti, Luisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2016 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: CD28(neg) T cells, which display functional characteristic of oligoclonally expanded cytotoxic memory T lymphocytes, are believed to be pathologically relevant in rheumatoid arthritis manifestation. The CD28 co-stimulation blockade by abatacept can prevent the generation of CD28(neg) T-cell populations in these patients | ||
| 520 | |a METHODS: Samples were obtained before and after 12 months of abatacept therapy. T-cell phenotype and T-cell receptor diversity were evaluated by flow cytometry and complementarity-determining region-3 spectratyping, respectively, while telomerase reverse-transcriptase gene level was measured by real-time PCR | ||
| 520 | |a RESULTS: Abatacept induces a decrease of the percentage and number of CD4(+)CD28(neg) T cells and a reduction of T-cell repertoire restrictions; these features are directly correlated. Thymic output and telomerase activity are not modified by the therapy | ||
| 520 | |a CONCLUSIONS: Abatacept-induced decrease of peripheral T-cell repertoire restrictions can due to a reduced generation of senescent, chronically stimulated CD4(+)CD28(neg) T cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Abatacept |2 NLM | |
| 650 | 7 | |a 7D0YB67S97 |2 NLM | |
| 650 | 7 | |a TERT protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.7.49 |2 NLM | |
| 650 | 7 | |a Telomerase |2 NLM | |
| 650 | 7 | |a EC 2.7.7.49 |2 NLM | |
| 700 | 1 | |a Scarsi, Mirko |e verfasserin |4 aut | |
| 700 | 1 | |a Zanotti, Cinzia |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarini, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoli, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Airò, Paolo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d 2003 |g 13(2015) vom: 16. Jan., Seite 12 |w (DE-627)NLM142679194 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2015 |g day:16 |g month:01 |g pages:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12967-014-0363-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2015 |b 16 |c 01 |h 12 | ||